Heart Failure with Preserved Ejection Fraction (HFpEF)

Iden fica on of HFpEF Using the H₂FPEF Score in Consecu vely Admi ed Pa entsWithout a Primary Heart Failure Diagnosis

by Prateek Chopra | May 31, 2026 | Cardiology Conferences | ESC-HF 2026 The 2021 European Society of Cardiology guidelines recommend a structured diagnostic approach incorporating clinical assessment, echocardiography, natriuretic peptides, and validated diagnostic scores such as the H₂FPEF score. With the availability of effective therapies capable of reducing morbidity and mortality in HFpEF, timely identification of affected patients has become […]

Iden fica on of HFpEF Using the H₂FPEF Score in Consecu vely Admi ed Pa entsWithout a Primary Heart Failure Diagnosis Read Post »

Leave a Comment / ESC-HF Day 4 / / / , , , ,

Prevention of Heart Failure With Non-pharmacological Interventions

by Prateek Chopra | May 21, 2026 | Cardiology Conferences | ESC-HF 2026 Heart failure (HF) prevention increasingly focuses on early modification of upstream cardiometabolic risk factors through lifestyle and dietary interventions. Emerging evidence suggests that non-pharmacological strategies targeting hypertension, obesity, diabetes, physical inactivity, and adverse dietary patterns may significantly reduce future HF risk, particularly heart failure with preserved ejection fraction

Prevention of Heart Failure With Non-pharmacological Interventions Read Post »

Leave a Comment / ESC-HF Day 2 / / / , , , ,

Phenotypic Clusters and Sacubitril/Valsartan in Heart Failure with PreservedEjec on Frac on: A PARAGON-HF Substudy

by Prateek Chopra | May 18, 2026 | Cardiology Conferences | ESC-HF 2026 Heart Failure with preserved ejection fraction (HFpEF) is a clinically heterogeneous syndrome with substantial variability in patient characteristics, prognosis, and therapeutic response. Despite advances in HF management, treatment outcomes in HFpEF remain inconsistent, likely reflecting differences in underlying pathophysiological mechanisms across patient subgroups. Machine learning–based phenotyping has emerged

Phenotypic Clusters and Sacubitril/Valsartan in Heart Failure with PreservedEjec on Frac on: A PARAGON-HF Substudy Read Post »

Leave a Comment / ESC-HF Day 1 / / / , , , ,

PRAISE-MR – ARNI in HFpEF with Secondary MR

by Prateek Chopra | May 17, 2026 | Cardiology Conferences | ESC-HF 2026 Atrial functional MR (AFMR) in HFpEF is characterized by preserved LV function with left atrial enlargement and mitral annular dilatation, differing from ventricular SMR. Although randomized AFMR-specific trials have been lacking, emerging evidence with ARNI, SGLT2i, ARBs, beta-blockers, CRT, and M-TEER suggests AFMR is a potentially treatable condition.

PRAISE-MR – ARNI in HFpEF with Secondary MR Read Post »

Leave a Comment / ESC-HF Day 1 / / / , , , ,

Renal Denervation in Chronic Heart Failure: A New Era Beyond Blood Pressure Control

by Prateek Chopra | June 3, 2026 | Cardiology Conferences | ESH 2026 Treatment Rationale: Renal denervation (RDN) is an emerging interventional strategy in chronic heart failure (CHF), particularly in patients with sympathetic nervous system (SNS) overactivity. Excessive SNS activation contributes to hypertension, cardiac remodeling, fibrosis, arrhythmias, endothelial dysfunction, renal sodium retention, and progression of heart failure. Mechanism of Action: Clinical

Renal Denervation in Chronic Heart Failure: A New Era Beyond Blood Pressure Control Read Post »

Leave a Comment / ESH Day 1 / / / , , , ,
Scroll to Top